Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846
Background: There is no standard treatment for stage IV soft tissue sarcoma (STS) after the failure of Adriamycin-based chemotherapy. This phase II study (NCT03121846) assessed the efficacy and safety of apatinib (YN968D1), a new tyrosine kinase inhibitor that targets VEGFR-2, for patients with stag...
Main Authors: | Xinyue Liu, Jin Xu, Feng Li, Zhichao Liao, Zhiwu Ren, Lei Zhu, Yehui Shi, Gang Zhao, Xu Bai, Jun Zhao, Ruwei Xing, Sheng Teng, Yun Yang, Jilong Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-02-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332219352096 |
Similar Items
-
Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy
by: Zhichao Liao, et al.
Published: (2020-05-01) -
Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
by: Tian Z, et al.
Published: (2019-06-01) -
Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
by: Lu Xie, et al.
Published: (2018-04-01) -
A Case Report of Primary Pulmonary Synovial Sarcoma with Postoperative Multiple Metastases Treated with Apatinib
by: Di ZHANG, et al.
Published: (2018-11-01) -
The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution
by: Wang Y, et al.
Published: (2020-07-01)